% | $
Quotes you view appear here for quick access.

Amylin Pharmaceuticals, Inc. Message Board

  • lovevegas2000 Jul 10, 2006 4:04 PM Flag

    loss of $.46 on 104 million revenues

    Amylin Pharmaceuticals Inc. saw demand for its diabetes drug Byetta outpace supply during the first quarter, and while analysts haven't cited the issue as a potential factor to the bottom line, they expressed concern over its impact during the next quarter.

    Citing price increases for Byetta that took effect in March, Bear Stearns analyst Mark Schoenebaum estimates the drug will bring in $80 million in revenue for the second quarter. Analysts expect a loss of 46 cents a share on sales of about $104 million for the quarter. The company is scheduled to report results July 24.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • If the market let iit, this is now the leader.
      Even more powerful than CELG.

      Up even while NASDAQ declined today!

      With NASDAQ back at its base, I would think AMLN will run up 10% very quickly.

      This is where the HOT money must go.

      ONeill and InvDaily CAN SLIM people will be buying this big-time tomorrow.

      SHort, you picked the wrong stock to short. Short one below its 50-day ma and one that is not breakiung out. YOU NEED O LEARN THE LESSON
      I AM HELPING YOU UNDERSTAND. I have been trading for 40 years!